Shearman Guides Sun Pharma To $3.2B Ranbaxy Merger
India's Sun Pharmaceuticals Inc. said Sunday it would take over struggling rival Ranbaxy Laboratories Ltd. in an all-stock deal worth $3.2 billion, betting big that it can helm a turnaround effort...To view the full article, register now.
Already a subscriber? Click here to view full article